Legato Capital Management LLC Sells 55,947 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Legato Capital Management LLC cut its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 23.1% during the fourth quarter, HoldingsChannel reports. The firm owned 186,424 shares of the company’s stock after selling 55,947 shares during the period. Legato Capital Management LLC’s holdings in Aquestive Therapeutics were worth $664,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in AQST. The Manufacturers Life Insurance Company bought a new position in shares of Aquestive Therapeutics in the second quarter worth about $76,000. Sanctuary Advisors LLC bought a new position in shares of Aquestive Therapeutics in the second quarter worth about $165,000. SG Americas Securities LLC increased its stake in shares of Aquestive Therapeutics by 58.9% in the third quarter. SG Americas Securities LLC now owns 25,619 shares of the company’s stock worth $128,000 after purchasing an additional 9,496 shares during the period. Creative Planning increased its stake in shares of Aquestive Therapeutics by 39.3% in the third quarter. Creative Planning now owns 92,822 shares of the company’s stock worth $462,000 after purchasing an additional 26,185 shares during the period. Finally, nVerses Capital LLC bought a new position in shares of Aquestive Therapeutics in the third quarter worth about $28,000. 32.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AQST. Leerink Partners boosted their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Finally, Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Trading Up 2.4 %

AQST stock opened at $3.47 on Friday. Aquestive Therapeutics, Inc. has a 1-year low of $2.24 and a 1-year high of $6.23. The firm has a market cap of $316.39 million, a P/E ratio of -7.71 and a beta of 2.67. The business’s 50 day moving average is $3.36 and its 200-day moving average is $4.20.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.